226 related articles for article (PubMed ID: 17545748)
1. An open-label, flexible-dose study of memantine in major depressive disorder.
Ferguson JM; Shingleton RN
Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
6. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
[TBL] [Abstract][Full Text] [Related]
7. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.
Keck PE; Hsu HA; Papadakis K; Russo J
Clin Neuropharmacol; 2009; 32(4):199-204. PubMed ID: 19620854
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
Schmitt L; Tonnoir B; Arbus C
Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
11. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
12. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
15. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study.
Lundt L
J Affect Disord; 2004 Aug; 81(2):173-8. PubMed ID: 15306145
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
17. Memantine in the treatment of binge eating disorder: an open-label, prospective trial.
Brennan BP; Roberts JL; Fogarty KV; Reynolds KA; Jonas JM; Hudson JI
Int J Eat Disord; 2008 Sep; 41(6):520-6. PubMed ID: 18433015
[TBL] [Abstract][Full Text] [Related]
18. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
[TBL] [Abstract][Full Text] [Related]
19. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
